Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B

Experimental and Toxicologic Pathology

Volumn 65, Issue 1-2, 2013, Pages 127-133

  Rodríguez, Sebastián ^a   Ito, Tsuyoshi ^a   He, Xi Jun ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Golden hamster; Monoamine oxidase B; MPP+; MPTP; Tyrosine hydroxylase (TH)

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL COUNT; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DISEASE RESISTANCE; DOPAMINERGIC NERVE CELL; ENDOTHELIUM CELL; ENZYME LOCALIZATION; FEMALE; MACROGLIA; MALE; NEUROTOXICITY; NONHUMAN; SUBSTANTIA NIGRA PARS COMPACTA; SUBVENTRICULAR ZONE;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; ASTROCYTES; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; CRICETINAE; DISEASE RESISTANCE; DOPAMINERGIC NEURONS; ENDOTHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MESOCRICETUS; MONOAMINE OXIDASE; MPTP POISONING; SEX FACTORS;

ANIMALIA; MESOCRICETUS AURATUS; MUS; PRIMATES;

EID: 84870248485     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.06.010     Document Type: Article

References (37)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995, 18:63-64.
2. Barcia C., Emborg M.E., Hirsch E.C., Herrero M.T. Blood vessels and parkinsonism. Front Biosci 2004, 9:277-282.
3. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985, 64:113-127.
4. Brooks W.J., Jarvis M.F., Wagner G.C. Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker. J Neural Transm 1988, 71:85-90.
5. Brooks W.J., Jarvis M.F., Wagner G.C. Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 1989, 76:1-12.
6. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 2009, 106:2933-2938.
7. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Jacobowitz D.M., Kopin I.J. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 1984, 20:548-553.
8. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979, 1:249-254.
9. Forno L.S., DeLanney L.E., Irwin I., Di Monte D., Langston J.W., Astrocytes Parkinson's disease. Prog Brain Res 1992, 94:429-436.
10. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1325.
11. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 1998, 70:1973-1978.
12. German D.C., Manaye K., Smith W.K., Woodward D.J., Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989, 26:507-514.
13. Hazell A.S., Itzhak Y., Liu H., Norenberg M.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 1997, 68:2216-2219.
14. He X.J., Nakayama H., Dong M., Yamauchi H., Ueno M., Uetsuka K., et al. Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. J Neuropathol Exp Neurol 2006, 65:873-882.
15. He X.J., Yamauchi H., Uetsuka K., Nakayama H. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease. Neurotoxicology 2008, 29:413-420.
16. Johannessen J.N., Chiueh C.C., Burns R.S., Markey S.P. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci 1985, 36:219-224.
17. Kalaria R.N., Harik S.I. Differential postnatal development of monoamine oxidases A and B in the blood-brain barrier of the rat. J Neurochem 1987, 49:1589-1594.
18. Kalaria R.N., Mitchell M.J., Harik S.I. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci U S A 1987, 84:3521-3525.
19. Kinemuchi H., Arai Y., Toyoshima Y. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. Neurosci Lett 1985, 58:195-200.
20. Kopin I.J. Features of the dopaminergic neurotoxin MPTP. Ann N Y Acad Sci 1992, 648:96-104.
21. Kupsch A., Sautter J., Gotz M.E., Breithaupt W., Schwarz J., Youdim M.B., et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001, 108:985-1009.
22. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
23. Marini A.M., Lipsky R.H., Schwartz J.P., Kopin I.J. Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J Neurochem 1992, 58:1250-1258.
24. Mitra N., Mohanakumar K.P., Ganguly D.K. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. J Neurochem 1994, 62:1906-1912.
25. Morin L.P., Wood R.I. A stereotaxic atlas of the golden hamster brain 2001, Academic Press, San Diego, CA; London.
26. Riachi N.J., Dietrich W.D., Harik S.I. Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. Brain Res 1990, 533:6-14.
27. Riachi N.J., Harik S.I., Kalaria R.N., Sayre L.M. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J Pharmacol Exp Ther 1988, 244:443-448.
28. Shibui Y., He X.J., Uchida K., Nakayama H. MPTP-induced neuroblast apoptosis in the subventricular zone is not regulated by dopamine or other monoamine transporters. Neurotoxicology 2009, 30:1036-1044.
29. Shults C.W. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta Neurol Scand Suppl 1993, 146:36-42.
30. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134:57-66.
31. Sonsalla P.K., Zeevalk G.D., German D.C. Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease. Parkinsonism Relat Disord 2008, 14(Suppl. 2):S116-S118.
32. Sundstrom E., Samuelsson E.B. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Pharmacol Toxicol 1997, 81:226-231.
33. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 1997, 94:9938-9943.
34. Trevor A.J., Castagnoli N., Caldera P., Ramsay R.R., Singer T.P. Bioactivation of MPTP: reactive metabolites and possible biochemical sequelae. Life Sci 1987, 40:713-719.
35. Trevor A.J., Singer T.P., Ramsay R.R., Castagnoli N. Processing of MPTP by monoamine oxidases: implications for molecular toxicology. J Neural Transm Suppl 1987, 23:73-89.
36. Wu W.R., Zhu X.Z., Guan H.J., Wang R.G., Ji X.Q. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity. Zhongguo Yao Li Xue Bao 1999, 20:146-150.
37. Zimmer J., Geneser F.A. Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. Neurosci Lett 1987, 78:253-258.